Zibotentan for the treatment of castrate-resistant prostate cancer

Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

(2010) Daniel C. Danila et al.   JOURNAL OF CLINICAL ONCOLOGY

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

(2010) Alison H.M. Reid et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054

(2009) James W. Growcott   ANTI-CANCER DRUGS

SPECIFIC ENDOTHELIN-A RECEPTOR ANTAGONISM FOR THE TREATMENT OF ADVANCED PROSTATE CANCER

(2009) Karim Fizazi et al.   BJU INTERNATIONAL

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

(2009) Celestia S. Higano et al.   CANCER

7013 Phase II trial of the specific endothelin A receptor antagonist zibotentan (ZD4054) in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer and bone metastases: final analysis of safety and efficacy

(2009) N.D. James et al.   EJC SUPPLEMENTS

Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer

(2009) P F Mulders et al.   PROSTATE CANCER AND PROSTATIC DISEASES

In vitrometabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers

(2009) H. C. Swaisland et al.   XENOBIOTICA

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

(2008) Joel B. Nelson et al.   CANCER

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial

(2008) Nicholas D. James et al.   EUROPEAN UROLOGY

ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer

(2008) Ruth Warren et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY

Endothelin Receptors and Pain

(2008) Alla Khodorova et al.   JOURNAL OF PAIN